Sono-Tek Reports Sixth Consecutive Quarter of Revenue Over $5 Million and 150% Annual Increase in Medical Market Sales
Sono-Tek Corporation reported financial results for the second quarter and first half of fiscal year 2026, ending August 31, 2025. The company recorded its sixth consecutive quarter with revenue exceeding $5 million and reported a 150% year-over-year increase in medical market sales. Fiscal first half net income rose 35%. The order backlog increased 50% sequentially. US/Canada sales decreased by $324,000, or 5% year-over-year, mainly due to lower demand in the clean energy sector. In Asia, sales increased by $647,000, or 74%, led by medical sales in China and alternative energy sales in Japan and South Korea. EMEA sales declined by $60,000, and Latin American sales decreased by $160,000, influenced by lower fluxing sales in Mexico. As of August 31, 2025, Sono-Tek held $10.6 million in cash, cash equivalents, and marketable securities, with no debt and stockholders' equity of $18.7 million. Capital expenditures for the first half of fiscal 2026 totaled $113,000. The company expects capital expenditures for the full fiscal year to reach approximately $300,000.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sono-Tek Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171520-25-000316), on October 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.